Connect with us

Business

Health Canada Chooses Mydecine Innovations Group Inc’s (OTCMKTS: MYCOF) Exclusive Dealer as a Licensed Supplier in Canada

Published

on

Mydecine Innovations Group Inc (OTCMKTS: MYCOF) recently announced that Health Canada added its supplier’s license to the Special Access Program. The Access Program authorizes medical physicians to appeal for certain drugs for their patients.

The program stipulates that other treatment options the patients received have not helped the patient. The poor response thus forces the physicians to request other drugs to facilitate the process.

Mydecine’s agreement with Applied Pharmaceutical Innovation

The company executed an agreement with Applied Pharmaceutical Innovation to distribute approved drugs throughout Canada. The agreement allowed Mydecine to access the dealer facility and distinguished research.

Mydecine also accessed and created adequate infrastructure and a facility in Edmonton, Canada. In the issuance of the license, the company offers drugs that meet the necessary practices of the program.

The Health Canada Program enables medical practitioners to request certain drugs for a patient affected with a life-threatening condition. In addition, the physicians request the drugs where the custom means of treatment are not suitable for various reasons, such as its unavailability in Canada.

The drug development process will enable the company to understand the needs and levels of their patients’ treatments. In addition, the acquired license allows the company to provide various drugs to several dispensaries across the country.

Mydecine develops therapies for mental health

The company creates and distributes innovative and novel therapeutics options for various mental health issues. Established in 2020, Mydecine creates and utilizes world-class technology and advanced infrastructure to develop other treatment options for patients.

Mydecine’s mission is to offer solutions to the absence of significant development of mental health treatment options. The company’s team creates new therapeutic options to treat mental health conditions such as depression, anxiety, etc.

Jeffy further added that its mission merges its technology and data results with clinical trials. As a result, Mydecine works closely with the necessary authorities to create new treatment plans that are more effective.

The company’s headquarters is in Colorado, USA, and it opened offices in the Netherlands to cater to its international consumers. In addition, Mydecine caters to patients who suffer from various issues such as mental health disorders and addiction.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.